BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Queensland Health
Boehringer Ingelheim
US Army

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,268,156

« Back to Dashboard

Which drugs does patent 7,268,156 protect, and when does it expire?

Patent 7,268,156 protects COREG CR and is included in one NDA. There have been three Paragraph IV challenges on Coreg CR.

Protection for COREG CR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 7,268,156

Title:Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
Abstract:The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat hypertension, congestive heart failure and angina, etc.
Inventor(s): Brook; Christopher S. (King of Prussia, PA), Chen; Wei (Woodbury, MN), Spoors; Paul G. (King of Prussia, PA)
Assignee: SB Pharmco Puerto Rico Inc. (Hato Rey, PR)
Application Number:10/518,654
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Smithkline Beecham
carvedilol phosphate
CAPSULE, EXTENDED RELEASE;ORAL022012-001Oct 20, 2006RXYesNo► Subscribe► SubscribeY
Smithkline Beecham
carvedilol phosphate
CAPSULE, EXTENDED RELEASE;ORAL022012-002Oct 20, 2006RXYesNo► Subscribe► SubscribeY
Smithkline Beecham
carvedilol phosphate
CAPSULE, EXTENDED RELEASE;ORAL022012-003Oct 20, 2006RXYesYes► Subscribe► SubscribeY
Smithkline Beecham
carvedilol phosphate
CAPSULE, EXTENDED RELEASE;ORAL022012-004Oct 20, 2006RXYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,268,156

PCT Information
PCT FiledJune 27, 2003PCT Application Number:PCT/US03/20408
PCT Publication Date:January 08, 2004PCT Publication Number: WO20/04/002419

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim
Daiichi Sankyo
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus